Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer

Creators: BOCCARDO, FRANCESCO; RUBAGOTTI, ALESSANDRA; Guglielmini, P; Sismondi, P; Farris, A; Amadori, D; Agostara, B; Gambi, A; Catalano, G; Faedi, M.

Others:: Boccardo, Francesco; Rubagotti, Alessandra; Guglielmini, P; Sismondi, P; Farris, A; Amadori, D; Agostara, B; Gambi, A; Catalano, G; Faedi, M.

Additional details